NCT02958969View on ClinicalTrials.gov

Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma

PHASE4CompletedINTERVENTIONAL

Enrollment

50

Participants

Timeline

Start Date

February 28, 2018

Primary Completion Date

June 30, 2019

Study Completion Date

November 19, 2019

Conditions

Venous ThromboembolismMultiple Myeloma

Interventions

DRUG

Apixaban

apixaban 2.5 mg orally twice daily for primary prevention of VTE for a duration of 6 months

Trial Locations (2)

37232

Vanderbilt University Medical Center, Nashville

02115

Brigham and Women's Hospital, Boston

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Gregory Piazza

OTHER